For several years stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated by the genetic mutation, called biomarkers, of the patient. A patient’s treatment was seen as either chemotherapy, immunotherapy (or some sort of combination of [...]
GO2 for Lung Cancer is a proud supporter of the recently passed Illinois State Bill (HB 1779), which requires Medicaid as well as state-regulated private insurance plans to cover comprehensive biomarker testing when supported by medical and scientific evidence. [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer New advances in lung cancer research were presented earlier this year at the 2020 World Conference on Lung Cancer (WCLC). Due to the COVID-19 pandemic, this conference [...]
By Daniel A. Saez, M.Sc., Treatment and Trials Navigator, GO2 for Lung Cancer In today’s lung cancer care landscape, biomarker testing has become a crucial part of the treatment decision for many oncologists. Targeted therapies can be more effective [...]
By Andrew Ciupek, Ph.D., Manager, Clinical Research, GO2 for Lung Cancer Approximately 30% of Non-Small Cell Lung Cancers (NSCLC) have an EGFR mutation. For these patients EGFR targeted therapy has greatly increased survival. Tagrisso (osimertinib) has become the drug [...]
In a year full of challenges for everyone, there was a silver lining for lung cancer patients in the form of the abundance of new approvals by the Food and Drug Administration (FDA). In 2020 there were approvals for [...]
We are pleased to announce that GO2 for Lung Cancer is part of a recently-awarded five-year grant from the National Cancer Institute as part of its new SeroNet initiative. This project seeks to uncover whether people with lung cancer, [...]
Comprehensive biomarker testing identifies what is unique about a lung cancer patient’s cancer, ensuring they receive appropriate treatment. Increasing the use of comprehensive biomarker testing is one of GO2 for Lung Cancer’s key goals. To reach it, we’re using [...]
Every person’s cancer is different. Between all of the lung cancer treatment options available, how can you and your treatment team identify the best path for your individual case? Enter: comprehensive biomarker testing. Comprehensive biomarker testing (also called molecular [...]
The lung cancer world now has therapies tied to individual biomarkers, making comprehensive biomarker testing an imperative at diagnosis. On August 18, our monthly Lung Cancer Living Room featured Dr. Benjamin Levy from Johns Hopkins University/Sidney Kimmel Comprehensive Cancer [...]